Zacks Investment Research·1d ago
What Makes LifeStance Health Group (LFST) a Strong Momentum Stock: Buy Now?Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
LifeStance appears to have achieved a structural profitability inflection, with revenue growth accelerating to 26.1% in 2026Q2 alongside a gross margin expansion to 35.2%, driving operating income to $30.7M from a $15.9M loss two years prior. The company's transformation to a net cash position ($225.9M cash vs.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.06+62.7% vs $0.04 | $456M+5.6% vs $432M |
Q3 2026 Aug 6, 2026 | $0.06+83.2% vs $0.03 | $435M+5.0% vs $415M |
Q2 2026 May 7, 2026 | $0.04+300.0% vs $0.01 | $404M+4.1% vs $387M |
Q1 2026 Feb 25, 2026 | $0.03 vs -$0.00 | $382M+1.0% vs $378M |
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
LifeStance Health (LFST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LifeStance Health Group NASDAQ: LFST raised its full-year 2026 outlook after reporting 25% third-quarter revenue growth, driven by more patient visits and higher revenue per visit. The mental health care provider also said its planned electronic health record transition could temper revenue growth in 2027.
LifeStance Health Group, Inc. (LFST) Q3 2026 Earnings Call Transcript
Benchmark LFST against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for LifeStance Health Group, Inc. (LFST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.77 | $5.34B | 74.92 | 13.85% | 4.29% | 4.82% | — | |
| $37.00 | $3.44B | -3.01 | 5.04% | -33.07% | -51.55% | — | |
| $195.50 | $11.83B | 7.91 | 9.71% | 7.96% | 19.27% | 0.41% | |
| $23.20 | $3.03B | -33.73 | 6.24% | -2.63% | -2.59% | — | |
| $31.65 | $4.97B | 22.13 | 13.03% | 3.74% | 16.36% | — | |
| $181.08 | $10.55B | 26.91 | 18.72% | 7.03% | 16.61% | 0.14% |
LifeStance Health Group, Inc. (LFST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
LifeStance Health Group, Inc. (LFST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 7, 2026·SEC
Jun 4, 2026·SEC
Get notified when LFST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LifeStance Health Group, Inc. (LFST) stock FAQ — growth, dividends, profitability & financials explained
LifeStance Health Group, Inc. (LFST) reported $1.68B in revenue over the trailing twelve months. Revenue was $1.42B in fiscal year 2025. That is 570% more than the $212.5M of fiscal year 2019.
LifeStance Health Group, Inc. (LFST) grew revenue by 22.6% over the trailing twelve months, compared with the twelve months before.
Yes. LifeStance Health Group, Inc. (LFST) earned $71.9M in net income over the trailing twelve months (a 4.3% net margin).
LifeStance Health Group, Inc. (LFST) had a return on equity (ROE) of 4.8% over the trailing twelve months. That is below the market's typical 10-15%.
LifeStance Health Group, Inc. (LFST) generated $215.4M in free cash flow over the trailing twelve months.
